“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

HealthDay News — Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations decreases ...

The decision came Tuesday from US District Judge Melissa DuBose in response to a lawsuit filed by attorneys general from 19 states and the District of Columbia, the Associated Press reported. DuBose ...

The wearable, transcutaneous neurostimulation device delivers personalized therapy using a proprietary AI algorithm.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

The Children’s Health Defense sued Meta Platforms, the parent company of Facebook and Instagram. It claimed the company removed their content in violation of free speech rights, NBC News reported.

We spoke with Dr Kellan Baker of the Whitman-Walker institute to shed some light on the many changes taking place to various aspects of medical care for LGBTQ+ individuals.

Decreases seen in mortality for acute MI, ischemic heart disease, while increases seen for mortality from other heart disease subtypes ...

Neither weighted vest use nor resistance training mitigates weight loss-linked bone loss in older adults with obesity ...